GOSS
Gossamer Bio Inc

2,585
Mkt Cap
$841.22M
Volume
4,972.00
52W High
$3.80
52W Low
$0.76
PE Ratio
-5.27
GOSS Fundamentals
Price
$3.62
Prev Close
$3.49
Open
$3.50
50D MA
$2.71
Beta
1.72
Avg. Volume
2.73M
EPS (Annual)
-$0.2499
P/B
-10.17
Rev/Employee
$791,041.38
Loading...
Loading...
News
all
press releases
Gossamer Bio (NASDAQ:GOSS) Hits New 1-Year High - Time to Buy?
Gossamer Bio (NASDAQ:GOSS) Hits New 12-Month High - What's Next...
MarketBeat·20h ago
News Placeholder
More News
News Placeholder
Gossamer Bio (NASDAQ:GOSS) Hits New 52-Week High - Should You Buy?
Gossamer Bio (NASDAQ:GOSS) Hits New 52-Week High - Still a Buy...
MarketBeat·20h ago
News Placeholder
Gossamer Bio (NASDAQ:GOSS) Stock Price Up 5.9% - Still a Buy?
Gossamer Bio (NASDAQ:GOSS) Shares Up 5.9% - Here's Why...
MarketBeat·8d ago
News Placeholder
Gossamer Bio, Inc. (NASDAQ:GOSS) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of Gossamer Bio, Inc. (NASDAQ:GOSS - Get Free Report) have received a consensus rating of "Moderate Buy" from the six ratings firms that are presently covering the company, MarketBeat reports...
MarketBeat·18d ago
News Placeholder
Gossamer Bio (NASDAQ:GOSS) Shares Up 7.4% - Should You Buy?
Gossamer Bio (NASDAQ:GOSS) Trading 7.4% Higher - Here's Why...
MarketBeat·27d ago
News Placeholder
Acadian Asset Management LLC Raises Position in Gossamer Bio, Inc. $GOSS
Acadian Asset Management LLC lifted its position in Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 12.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with...
MarketBeat·29d ago
News Placeholder
FY2025 Earnings Forecast for Gossamer Bio Issued By Wedbush
Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Stock analysts at Wedbush lowered their FY2025 EPS estimates for shares of Gossamer Bio in a report issued on Thursday, November 6th. Wedbush analyst...
MarketBeat·1mo ago
News Placeholder
Gossamer Bio to Participate in Upcoming Investor Conferences
Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial...
Business Wire·1mo ago
News Placeholder
Gossamer Bio (NASDAQ:GOSS) Issues Earnings Results, Misses Expectations By $0.02 EPS
Gossamer Bio (NASDAQ:GOSS - Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by...
MarketBeat·1mo ago
News Placeholder
Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates
Gossamer Bio (GOSS) delivered earnings and revenue surprises of -10.53% and +118.76%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago

Latest GOSS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.